Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
August 17, 2026 — VivoSim Labs, Inc. (NASDAQ: VIVS) is gaining investor attention as its 3D human tissue models, artificial intelligence and New Approach Methodologies (NAMs) target one of pharmaceutical development’s biggest challenges: identifying drug toxicity before costly clinical trials.
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.
Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.
FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors.
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.
Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited grow...
Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from El
